Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Interest & Investment Income (2016 - 2025)

Seres Therapeutics' Interest & Investment Income history spans 11 years, with the latest figure at $618000.0 for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 5.21% year-over-year to $618000.0; the TTM value through Sep 2025 reached $2.2 million, down 59.66%, while the annual FY2024 figure was $4.0 million, 45.66% down from the prior year.
  • Interest & Investment Income for Q3 2025 was $618000.0 at Seres Therapeutics, up from $546000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.6 million in Q3 2023 and bottomed at $384000.0 in Q1 2022.
  • The 5-year median for Interest & Investment Income is $829000.0 (2021), against an average of $998842.1.
  • The largest annual shift saw Interest & Investment Income soared 1020.27% in 2021 before it tumbled 77.83% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $485000.0 in 2021, then surged by 191.55% to $1.4 million in 2022, then skyrocketed by 39.39% to $2.0 million in 2023, then crashed by 77.83% to $437000.0 in 2024, then skyrocketed by 41.42% to $618000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Interest & Investment Income are $618000.0 (Q3 2025), $546000.0 (Q2 2025), and $618000.0 (Q1 2025).